New Delhi: Epigral Limited (Epigral), India’s leading integrated chemical manufacturer, today announced its financial results for the quarter ended June 30, 2025. The company posted a revenue of ₹ 615 Crore for the quarter ended June 30th, 2025 as against ₹ 654 Crore recorded in Q1YF25. During the quarter under review, PAT stood at ₹ 160 Crore (includes decrease in deferred tax liability of ₹ 81 Cr) compared to ₹ 86 Crore in Q1FY25.
Commenting on the results Mr. Maulik Patel; Chairman and Managing Director – Epigral said: “Q1FY26 quarter ended with slightly lower volume and drop in realizations, however we maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2FY26 to be stronger compared to H1FY26. Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase. Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget. We are still left with a land parcel in the current complex for which we will announce a capex to further strengthen our integrated complex.
The key performance highlights:
Q1FY26 Operational and Financial Highlights:
o Plant utilization stood at 73%
o ROCE grew to 24% as on 30th June 2025 vs 21% as on 30th June 2024 due to improved earnings
o Net Debt/EBITDA reduced to 0.6x as on 30th June 2025 vs 1.6x as on 30th June 2024 on account of
improvement in EBITDA and reduction in Net Debt
o YoY Revenue dropped by 6% to ₹ 615 Crore. Revenue contribution from Derivatives & Specialty business
stood at 50%
o EBITDA dropped by 7% to ₹ 163 Crore, however EBITDA margin remained unchanged at 27% on account of
sustained focus on efficiency and product mix
o PAT stood at ₹ 160 Cr, however PAT excluding deferred tax liability benefit stood at ₹ 79 Cr as against ₹ 86
Crore in Q1FY25
Strategic Updates:
o Epigral Capex plans are moving as per schedule and are expected to get commissioned within the timeline
and budget
o CPVC Resin capacity will reach to 1,50,000 TPA, by adding additional 75,000 TPA
o Epichlorohydrin capacity will reach to 1,00,000 TPA, by adding additional 50,000 TPA
o Wind Solar Hybrid Power Plant capacity will reach to 38.14 MW, by adding additional 19.80 MW
o Epigral commissioned India’s 1st Chlorotoluenes Value Chain plant in March 2025.
